Literature DB >> 10027332

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.

O Falcón1, R Chirino, L León, A López-Bonilla, S Torres, L Fernández, J A García-Hernández, P F Valerón, J C Díaz-Chico.   

Abstract

Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I-III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg(-1) protein (median 44 pmol mg(-1) protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027332      PMCID: PMC2362431          DOI: 10.1038/sj.bjc.6690090

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Cathepsin D: an independent prognostic factor for metastasis of breast cancer.

Authors:  F Spyratos; T Maudelonde; J P Brouillet; M Brunet; A Defrenne; C Andrieu; K Hacene; A Desplaces; J Rouëssé; H Rochefort
Journal:  Lancet       Date:  1989-11-11       Impact factor: 79.321

2.  Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells.

Authors:  F Capony; C Rougeot; P Montcourrier; V Cavailles; G Salazar; H Rochefort
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

3.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

4.  The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease.

Authors:  M Morisset; F Capony; H Rochefort
Journal:  Biochem Biophys Res Commun       Date:  1986-07-16       Impact factor: 3.575

5.  Stage I endometrial adenocarcinoma: treatment results in 835 patients.

Authors:  R J Lotocki; L J Copeland; A D DePetrillo; W Muirhead
Journal:  Am J Obstet Gynecol       Date:  1983-05-15       Impact factor: 8.661

6.  Carcinoma of the endometrium: stage I.

Authors:  G D Malkasian; J F Annegers; K S Fountain
Journal:  Am J Obstet Gynecol       Date:  1980-04-01       Impact factor: 8.661

7.  Purification and first characterization of the secreted and cellular 52-kDa proteins regulated by estrogens in human-breast cancer cells.

Authors:  F Capony; M Garcia; J Capdevielle; C Rougeot; P Ferrara; H Rochefort
Journal:  Eur J Biochem       Date:  1986-12-01

8.  Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease.

Authors:  W M Christopherson; P J Connelly; R C Alberhasky
Journal:  Cancer       Date:  1983-05-01       Impact factor: 6.860

9.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.

Authors:  S M Thorpe; H Rochefort; M Garcia; G Freiss; I J Christensen; S Khalaf; F Paolucci; B Pau; B B Rasmussen; C Rose
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

10.  Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis.

Authors:  G Ferrandina; G Scambia; F Bardelli; P Benedetti Panici; S Mancuso; A Messori
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  5 in total

1.  DICER1 expression and outcomes in endometrioid endometrial adenocarcinoma.

Authors:  Israel Zighelboim; Andrew J Reinhart; Feng Gao; Amy P Schmidt; David G Mutch; Premal H Thaker; Paul J Goodfellow
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

2.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

Review 3.  Carcinoma of the endometrium.

Authors:  B M Southcott
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer.

Authors:  Cristina Bilbao-Sieyro; Raquel Ramírez; Germán Rodríguez-González; Orlando Falcón; Laureano León; Santiago Torres; Leandro Fernández; Sergio Alonso; Nicolás Díaz-Chico; Manuel Perucho; Juan Carlos Díaz-Chico
Journal:  Oncotarget       Date:  2014-08-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.